Akutsu Hiroyoshi, Kreutzer Jürgen, Fahlbusch Rudolf, Buchfelder Michael
Department of Neurosurgery, University of Erlangen-Nürnberg, Erlangen, Germany.
Neurosurgery. 2009 Jul;65(1):54-62; discussion 62. doi: 10.1227/01.NEU.0000348016.69726.A6.
The aim of this study was to assess the outcome of cranial nerve and endocrine function after transsphenoidal decompression for symptomatic cavernous sinus (CS) meningioma.
Between 1991 and 2007, 21 patients (19 women and 2 men; mean age, 51.1 +/- 10.6 years) harboring symptomatic CS meningiomas underwent transsphenoidal decompression. Sufficient bone removal, opening of the inferomedial wall of the CS, and tumor debulking were performed.
Notably, the grading of preoperative optomotoric paresis improved in 15 of the 17 patients who presented with that symptom. Complete recovery could be achieved in 8 patients. Complete recovery rates in patients with preoperative grading of "good," "fair," and "poor" were 77.7%, 20%, and 0%, respectively (P = 0.0088). Improvement of cranial nerve dysfunction was found in 32 of 34 deficits. No worsening of cranial nerve function occurred. Endocrinologically, the prolactin level was normalized in 13 of the 17 patients with preoperative hyperprolactinemia. Recovery of growth hormone deficiency and hypogonadism were found in 3 patients (37.5%) and 1 patient (33.3%), respectively. Seventeen patients were followed for more than 3 years. Of these 17 patients, 12 patients received initial postoperative adjuvant radiotherapy. The overall tumor control rate after surgery with initial adjuvant radiotherapy was 100% (median follow-up, 65 months; range, 36-126 months).
Transsphenoidal decompression is a safe and effective treatment to improve cranial nerve and endocrine dysfunction in patients with symptomatic CS meningiomas. The less severe optomotoric nerve palsy before surgery, the better the chance of complete recovery of its function. Combined with adjuvant radiotherapy, this minimally invasive management also provided excellent long-term tumor control.
本研究旨在评估经蝶窦减压术治疗有症状海绵窦(CS)脑膜瘤后颅神经和内分泌功能的结果。
1991年至2007年间,21例有症状CS脑膜瘤患者(19例女性,2例男性;平均年龄51.1±10.6岁)接受了经蝶窦减压术。进行了充分的骨质去除、打开CS的内侧下壁和肿瘤减容。
值得注意的是,17例出现该症状的患者中有15例术前动眼神经麻痹分级得到改善。8例患者可实现完全恢复。术前分级为“良好”“中等”和“差”的患者完全恢复率分别为77.7%、20%和0%(P = 0.0088)。34处神经功能缺损中有32处颅神经功能得到改善。未出现颅神经功能恶化。内分泌方面,17例术前高催乳素血症患者中有13例催乳素水平恢复正常。分别有3例(37.5%)和1例(33.3%)患者的生长激素缺乏和性腺功能减退得到恢复。17例患者随访超过3年。在这17例患者中,12例患者术后接受了初始辅助放疗。初始辅助放疗术后的总体肿瘤控制率为100%(中位随访时间65个月;范围36 - 126个月)。
经蝶窦减压术是改善有症状CS脑膜瘤患者颅神经和内分泌功能障碍的一种安全有效的治疗方法。术前动眼神经麻痹越不严重,其功能完全恢复的机会越好。结合辅助放疗,这种微创治疗方法也能提供出色的长期肿瘤控制效果。